Temporal Heterogeneous in the Effectiveness of Inactivated CoronaVac and Sinopharm Vaccines Against SARS‐CoV‐2 Reinfections in China
Transboundary and Emerging Diseases · 2024
DOI: 10.1155/2024/9533861 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transboundary and Emerging Diseases, 2024. Verfasst von Shihong Yang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease Dalian Center for Disease Control and Prevention, Dalian, Liaoning Province, China. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, SARS-CoV-2, Reinfection. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
We aimed to understand the temporal dynamics of SARS‐CoV‐2 reinfection risk and assess the impact of inactivated vaccination on the occurrence of reinfection. We investigated the reinfection risk of SARS‐CoV‐2 from November 1, 2022, to February 12, 2023, when China rapidly lifted the zero‐COVID policy. The study subjects were those who were first infected during the zero‐COVID period between January 1, 2020, and October 31, 2022, in Dalian city, China. Among the 1961 previous infections, 126 (6.4%, 95% CI: 5.4, 7.5) were reinfected. The risk of reinfection increased over time since initial infection. Compared with those who did not receive or received one dose of inactivated vaccine, receiving two or three doses was associated with additional protection against reinfection among individuals who were infected with pre‐Omicron more than a year earlier, with the OR ranged from 0.33 (95% CI: 0.03, 1.83) to 0.91 (95% CI: 0.22, 3.27). In contrast, no protective effect from two or three doses of vaccines against reinfection was observed among those who were first infected with Omicron variants within a year. Primary or booster vaccination contributed to limited protection against reinfection or symptomatic reinfection among individuals infected with Omicron SARS‐CoV‐2 within a year. However, a booster dose after 1 year of natural infection may provide additional protection against reinfection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Disease Dalian Center for Disease Control and Prevention, Dalian, Liaoning Province, China.
- School of Population Medicine and Public Health Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- World Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control School of Public Health Li Ka Shing Faculty of Medicine The University of Hong Kong, Hong Kong, China.
- Department of Infectious Disease Control and Prevention Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, China.
- Division of Infectious Disease Chinese Center for Disease Control and Prevention, Beijing, China.
- WorldPop School of Geography and Environmental Science University of Southampton, Southampton, UK.
ORCID-Profile: Zhongjie Li
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Yang, S., Xin, H., Lang, X., Hua, J., Cui, X., Li, L., Ye, C., Qin, Y., Li, Y., Cowling, B., Lai, S., Sun, K., & Li, Z. (2024). Temporal Heterogeneous in the Effectiveness of Inactivated CoronaVac and Sinopharm Vaccines Against SARS‐CoV‐2 Reinfections in China. Transboundary and Emerging Diseases. https://doi.org/10.1155/2024/9533861
Vancouver
Yang S, Xin H, Lang X, Hua J, Cui X, Li L, et al. Temporal Heterogeneous in the Effectiveness of Inactivated CoronaVac and Sinopharm Vaccines Against SARS‐CoV‐2 Reinfections in China. Transboundary and Emerging Diseases. 2024. doi:10.1155/2024/9533861
BibTeX
@article{Yang2024,
author = {Yang, Shihong and Xin, Hualei and Lang, Xingying and Hua, Jin and Cui, Xiaoman and Li, Lu and Ye, Chuchu and Qin, Ying and Li, Yu and Cowling, Ben and Lai, Shengjie and Sun, Ke and Li, Zhongjie},
title = {Temporal Heterogeneous in the Effectiveness of Inactivated CoronaVac and Sinopharm Vaccines Against SARS‐CoV‐2 Reinfections in China},
journal = {Transboundary and Emerging Diseases},
year = {2024},
doi = {10.1155/2024/9533861}
}
EUVIMED